Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Narrative) (Details)

v3.22.1
Stockholders' Equity (Narrative) (Details)
 1 Months Ended 3 Months Ended 8 Months Ended
Oct. 31, 2021
$ / shares
Oct. 29, 2019
$ / shares
shares
Jun. 26, 2018
shares
Feb. 23, 2017
USD ($)
shares
Sep. 30, 2021
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
shares
Jun. 30, 2020
USD ($)
shares
Nov. 01, 2021
$ / shares
shares
Jun. 30, 2021
USD ($)
shares
Dec. 31, 2020
shares
Jun. 20, 2018
shares
Stockholders' Equity [Line Items]                        
Preferred Stock, shares authorized       1,000,000   1,000,000            
Common stock, shares authorized (in shares)           275,000,000       275,000,000    
Exercise of stock options (in shares)         84,500              
Exercise of warrants (in shares)               29,100,000        
Proceeds from exercise of warrants | $               $ 6,400,000        
Shares of common stock issued for the cashless exercise of Warrants               5,900,000        
Cashless exercise of warrants reducing balance owed for notes payable - warrant exchange | $               $ 1,300,000        
Costs related to the warrant exchange offset against additional paid-in capital | $               $ 313,000        
Weighted average risk-free interest rate                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions           0.23            
Dividend yield                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions           0            
Volatility                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions           136.9            
Expected term (in years)                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions           4.95            
College Station Investors LLC And Bryan Capital [Member]                        
Stockholders' Equity [Line Items]                        
Warrants, exercise price per share | $ / shares                 $ 1.33      
Warrants to purchase shares of Common Stock                 1,289,581      
Series A Common Stock Purchase Warrants [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued   25,000,000                    
Warrants, exercise price per share | $ / shares   $ 0.22                    
Term of the warrants   2 years                    
Warrants outstanding                     0  
Series B Common Stock Purchase Warrants [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued   25,000,000                    
Warrants, exercise price per share | $ / shares   $ 0.22                    
Term of the warrants   7 years                    
Warrants outstanding                     0  
Series A Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Preferred stock, shares outstanding (in shares)           0            
Preferred stock, par value (in dollars per share) | $ / shares           $ 0.001            
Number of shares designated                       6,300
Number of common stock issued upon conversion     8,357,997                  
Series B Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Preferred stock, shares outstanding (in shares)           0            
Preferred stock, par value (in dollars per share) | $ / shares           $ 0.001            
Number of common stock issued upon conversion     28,935,000                  
Series C Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Preferred stock, shares outstanding (in shares)           0            
Preferred stock, par value (in dollars per share) | $ / shares           $ 0.001            
Number of common stock issued upon conversion   22,550,000                    
iBio CMO Preferred Tracking Stock [Member]                        
Stockholders' Equity [Line Items]                        
Preferred Stock, Dividend Rate, Percentage       2.00%                
Preferred Stock, Dividends Per Share, Declared | $ / shares $ 0                      
Preferred stock, shares outstanding (in shares)                 0      
Dividends Payable | $           $ 0       $ 1,131,000    
Restricted Stock Units [Member]                        
Stockholders' Equity [Line Items]                        
Shares vested           105,027 103,003          
Omnibus Incentive (the 2020) Plan [Member]                        
Stockholders' Equity [Line Items]                        
Shares available for grant under the plan           32,000,000            
Underwritten Public Offering [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued     6,300                  
Underwritten Public Offering [Member] | Series B Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued     5,785                  
Underwritten Public Offering [Member] | Series C Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued   4,510                    
Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Bioprocessing (iBio CDMO) [Member]                        
Stockholders' Equity [Line Items]                        
Stock Issued During Period, Shares, Acquisitions       1                
Number of LLC interest units exchanged for each share of preferred tracking stock       29,990,000                
Proceeds from sale of shares, net of issuance cost | $       $ 13,000,000                
Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]                        
Stockholders' Equity [Line Items]                        
Noncontrolling Interest, Ownership Percentage by Parent       99.99%                
Exchange Agreement [Member] | Eastern Affiliate [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]                        
Stockholders' Equity [Line Items]                        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       0.01%